COMPLIANCE INFO_1980-2010 - Laserfiche WebLink

Home Browse Search

0 State of California -Health and Human Servgency Department of Health Services Page 4 of 5 pages License Number: 1368-39 Amendment Number: 30 20. The licensee may use one constancy source for the dose calibrator constancy test provided that the dose calibrator manual indicates that only one constancy source is needed for proper Quality Control. 21. The licensee may use any commercially available device, acceptable to the U.S. Nuclear Regulatory Commission, an Agreement State or a Licensing State, for doing linearity tests of its dose calibrator provided the procedures described by the manufacturer of the linearity device are followed. 22. Nuclear medicine technology procedures shall be performed by nuclear medicine technologists pursuant to Title 17, California Code of Regulations, Subchapter 4.6. Such procedures shall be performed under the supervision of individuals listed as authorized users on this license who meet the criteria specified in Section 30510. Certificates or special permits issued pursuant to Subchapter 4.6 shall be prominently displayed at the facility authorized on this license. 23. Treatment and management of patients receiving therapeutic quantities of unsealed radioactive materials shall be in accordance with the guidance from any of the following: (a) Chapter 4, "Release from Hospital of Patients Containing Radioactive Material" National Council on Radiation Protection and Measurements (NCRP) Report No. 37, "Precautions in the Management of Patients Who Have Received Therapeutic Amounts of Radionuclides" (NCRP Publications, P.O. Box 30175, Washington, D.C. 20014). (b) Appendix M in the "Guide for the Preparation of Applications for Medical Programs", State of California, Department of Health Services, Radiological Health Branch. (c) Documented rationale or patient -specific calculations demonstrating that members of the general public will be limited to 500 mrem total effective dose equivalent from patients who have been released containing therapeutic quantities of radiopharmaceuticals. 24. Treatment and management of patients undergoing brachytherapy shall be in accordance with the guidance from any of the following: (a) Chapter 5, "Safety Precautions in Clinical Application", National Council on Radiation Protection and Measurements (NCRP) Report No. 40, "Protection Against Radiation From Brachytherapy Sources" (NCRP Publications, P.O. Box 30175, Washington, D.C. 20014). b) ADpendix N in the "Guide for the Preparation of Applications for . Medical Programs", State of California, Department of Health Services, Radiological Health Branch. (c) Documented rationale or patient -specific calculations demonstrating that members of the general public will be limited to 500 mrem total effective dose equivalent from patients who have been released containing therapeutic quantities of radionuclides. 25. If there is reason to suspect that a medical radium source may be leaking or contaminated, it shall be tested before further use, by a method acceptable to the Department of Health Services, and a report of the test results and the action taken shall be submitted within 30 days to the Radiologic Health Branch. 26. Production or processing of radiopharmaceuticals for the purpose of commercial distribution to other licensees is not authorized by this license.